Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
GENB Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 19, 2026
Report Source: 2026 1st Quarter Report
Generate Biomedicines Inc. Stock Analysis GENB
United States Health Care Small Cap Report: Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company is headquartered in Somerville, Massachusetts and currently employs 312 full-time employees. The company went IPO on 2026-02-27. The firm is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.
Read More Generate Biomedicines Inc (GENB) Chart
Key Statistics of Generate Biomedicines Inc (GENB)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$15.44Volume
832.10KP/E Ratio (TTM)
-52 Week Range
Market Cap
1.79BAvg. Volume
954.45KDividend Yield
-Financial Metrics & Statements of Generate Biomedicines Inc (GENB)
FAQ's for Generate Biomedicines Inc (GENB)
- According to Musaffa’s Shariah screening methodology, Generate Biomedicines Inc (GENB) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Generate Biomedicines Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Generate Biomedicines Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Generate Biomedicines Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Generate Biomedicines Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Generate Biomedicines Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.